Earlier this year, we published the first clinical findings showing engineered CAR-T cells can deplete pathogenic B cells in patients with progressive multiple sclerosis. This breakthrough supports continued research into a differentiated approach compared to traditional treatments. Our CMO James Chung discusses KYV-101, our product candidate's unique characteristics with Nature’s Charlotte Harrison in treating autoimmune diseases. He highlights that KYV-101's CAR construct is intended to be well-suited for such conditions due to its fully human CD19 antibody domain, designed to reduce immunogenicity, and its optimization for safety. To gather more data, Dr. Chung also shares how we’re collaborating with Stanford University on a US-based phase 1 MS trial and conducting a phase 2 MS trial in the US and Europe. #KYV101 #CARTCellTherapy #multiplesclerosis https://lnkd.in/eQ9UKbSd
Fantastic article!
Managing Director, Consort Partners
1moExcellent interview and commentary from James in this story.